Tirzepatide

Tirzepatide is a once-weekly dual GIP and GLP-1 receptor agonist approved for type 2 diabetes (Mounjaro) and chronic weight management (Zepbound). The dual incretin action produces greater weight loss and HbA1c reduction than selective GLP-1 agonists in head-to-head trials; the FDA approved Zepbound for moderate-to-severe obstructive sleep apnea in adults with obesity in December 2024, while cardiovascular outcome benefits remain under investigation. Longevity-relevant effects parallel GLP-1 agonists: improved metabolism, weight reduction, and reduced cardiometabolic risk. Off-label use in metabolically healthy adults for lifespan extension remains investigational.